Retatrutide: Lilly’s New Drug Slashes Weight & Blood Sugar | GLP-1 Advances

Eli Lilly’s experimental drug retatrutide delivered significant reductions in blood sugar and prompted an average weight loss of 15.3% in a late-stage clinical trial for Type 2 diabetes, the pharmaceutical company announced last week.

The once-weekly injectable medication, dubbed “triple-G” by analysts due to its activation of three key hormones, demonstrated substantial improvements in metabolic health among trial participants over a nine-month period, according to Lilly. Patients on the highest dose also experienced a 1.9% reduction in A1C levels, a measure of long-term blood sugar control.

“Retatrutide delivers the highest levels of weight loss we’ve seen from an obesity drug to date,” Scotiabank analyst Louise Chen told Reuters.

The results come as the market for glucagon-like peptide-1 (GLP-1) drugs, initially developed for diabetes treatment, has exploded due to their effectiveness in weight loss. Approximately one in eight Americans are now using medications like Ozempic or Wegovy, according to a recent KFF survey, for conditions ranging from diabetes and heart disease to weight management.

Retatrutide distinguishes itself from existing GLP-1 treatments by simultaneously activating GLP-1, GIP and glucagon receptors. This “triple agonist” approach is expected to yield greater weight loss and metabolic benefits than drugs targeting only one or two of these hormones, according to industry observers.

The potential market for these incretin hormones is substantial, with J.P. Morgan Global Research forecasting a $200 billion global market by 2030.

While injectable medications currently dominate the market, pharmaceutical companies are also developing oral formulations. Novo Nordisk received FDA approval in December for Wegovy, the first GLP-1 weight-loss pill, and approximately 400,000 Americans have begun using it, CNN reported.

Eli Lilly is also pursuing an oral option, with plans to introduce orforglipron pending regulatory approval as early as next quarter.

Innovation in the field continues, with researchers exploring drugs that activate even more hormone receptors. Kirk Habegger, a professor of medicine at the University of Alabama at Birmingham, recently described a presentation he attended detailing a five-receptor drug in development. He suggested that targeting specific cell types could mitigate potential side effects associated with activating nuclear hormone receptors.